Mediwhale Dr. Eye CVD Featured at ESC for 2nd Consecutive Year

Mediwhale's innovative AI medical device 'Dr. NooN CVD' once again proved its technological prowess by garnering international attention for the second consecutive year at the European Society of Cardiology Congress (ESC Congress 2025) held in Madrid, Spain. Amidst cardiovascular disease diagnosis and treatment utilizing digital technology emerging as a major topic, Dr. NooN CVD, a groundbreaking AI software that predicts the risk of future cardiovascular disease with accuracy comparable to cardiac CT solely through retinal imaging, earned the honor of being an invited presenter for the second consecutive year. Professor Park Sung-ha of Severance Hospital, Yonsei University Health System, who was responsible for the clinical validation of Dr. NooN CVD, served as an invited speaker at this academic conference. Professor Park unveiled research results from a prospective analysis of outpatient data from Severance Cardiology over two years, clearly presenting the academic basis for retinal image-based cardiovascular risk assessment and successful application cases of AI technology. In particular, he deeply explored the strong correlation between Dr. NooN CVD and the risk of cardiovascular and cerebrovascular diseases, drawing the keen attention of the attendees. Dr. NooN CVD is already being recognized for its utility and utilized at major overseas medical institutions, including domestic Severance Hospital, as well as GluCare.Health in Dubai and the American Hospital Rome in Italy. Mediwhale, through an experience booth within the exhibition hall, allowed visitors to directly check their cardiovascular risk through retinal imaging and provided a platform for in-depth discussions with global experts on practical application methods. Mediwhale is a leading company that has developed and commercialized AI solutions for cardiovascular disease prevention through eye examinations. Currently, the company is actively preparing to enter the U.S. market, targeting De Novo approval from the U.S. Food and Drug Administration (FDA) in 2026, and since May of this year, it has been accelerating its domestic business expansion through cooperation with Dong-A ST. Choi Tae-geun, CEO of Mediwhale, stated, "The fact that Dr. NooN CVD was introduced at the European Society of Cardiology for two consecutive years among numerous innovative technologies is clear evidence that our technological value has been recognized," and expressed his ambition, "We will continuously strive to establish ourselves as a new standard for cardiovascular risk assessment in more medical settings in the future."